Overview
- Peptide (C)HAREATQRPRD(S)EVE, corresponding to amino acid residues 225-239 of rat TBXA2R (Accession P34978). 3rd intracellular loop.
- Mouse and rat brain lysates, human THP-1 monocytic leukemia cell line lysate and human MEG-01 megakaryoblastic leukemia cell line lysate (1:200-1:600).
- Western blot analysis of mouse (lanes 1 and 3) and rat (lanes 2 and 4) brain lysates:1,2. Anti-Thromboxane A2 Receptor Antibody (#APR-069), (1:200).
3,4. Anti-Thromboxane A2 Receptor Antibody, preincubated with Thromboxane A2 Receptor Blocking Peptide (#BLP-PR069). - Western blot analysis of human THP-1 monocytic leukemia (lanes 1 and 3) and human MEG-01 megakaryoblastic leukemia (lanes 2 and 4) cell line lysates:1,2. Anti-Thromboxane A2 Receptor Antibody (#APR-069), (1:200).
3,4. Anti-Thromboxane A2 Receptor Antibody, preincubated with Thromboxane A2 Receptor Blocking Peptide (#BLP-PR069).
- Mouse brain sections (1:200).
Thromboxane A2 (TxA2) is a prostanoid that is synthesized from arachidonic acid and plays an important role in haemostasis, a process regulating platelet aggregation and vascular tone. Thromboxane A2 binds to the thromboxane A2 receptor (TBXA2R) to induce strong vasoconstriction in renal arteries.
Thromboxane A2 receptor is a seven-transmembrane G-protein coupled receptor localized on the cell membrane and in intracellular compartments. TBXA2R is expressed in the central nervous system in several types of cells, such as microglia, oligodendrocytes and astrocytes. Imbalances in the levels of the receptor is widely implicated in several cardiovascular, pulmonary, renal and prostate pathologies1-3.
Thromboxane A2 receptor mediates vasoconstriction and ischemia and its activation is implicated in atherosclerosis and inflammation. Activation of the receptor induces endothelial cell apoptosis by inhibiting Akt phosphorylation and also inhibits endothelial cell migration and angiogenesis by decreasing Akt and eNOS phosphorylation1-3.